Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer.

Autor:	Ogunleye A; Department of Organismal Biology, Uppsala University, Uppsala, Sweden., Piyawajanusorn C; Department of Bioengineering, Imperial College London, London, UK., Ghislat G; Department of Life Sciences, Imperial College London, London, UK., Ballester PJ; Department of Bioengineering, Imperial College London, London, UK.
Jazyk:	angličtina
Zdroj:	Health data science [Health Data Sci] 2024 Jan 08; Vol. 4, pp. 0108. Date of Electronic Publication: 2024 Jan 08 (Print Publication: 2024).
DOI:	10.34133/hds.0108
Abstrakt:	Background: Gemcitabine is a first-line chemotherapy for pancreatic adenocarcinoma (PAAD), but many PAAD patients do not respond to gemcitabine-containing treatments. Being able to predict such nonresponders would hence permit the undelayed administration of more promising treatments while sparing gemcitabine life-threatening side effects for those patients. Unfortunately, the few predictors of PAAD patient response to this drug are weak, none of them exploiting yet the power of machine learning (ML). Methods: Here, we applied ML to predict the response of PAAD patients to gemcitabine from the molecular profiles of their tumors. More concretely, we collected diverse molecular profiles of PAAD patient tumors along with the corresponding clinical data (gemcitabine responses and clinical features) from the Genomic Data Commons resource. From systematically combining 8 tumor profiles with 16 classification algorithms, each of the resulting 128 ML models was evaluated by multiple 10-fold cross-validations. Results: Only 7 of these 128 models were predictive, which underlines the importance of carrying out such a large-scale analysis to avoid missing the most predictive models. These were here random forest using 4 selected mRNAs [0.44 Matthews correlation coefficient (MCC), 0.785 receiver operating characteristic-area under the curve (ROC-AUC)] and XGBoost combining 12 DNA methylation probes (0.32 MCC, 0.697 ROC-AUC). By contrast, the hENT1 marker obtained much worse random-level performance (practically 0 MCC, 0.5 ROC-AUC). Despite not being trained to predict prognosis (overall and progression-free survival), these ML models were also able to anticipate this patient outcome. Conclusions: We release these promising ML models so that they can be evaluated prospectively on other gemcitabine-treated PAAD patients. Competing Interests: Competing interests: The authors declare that they have no competing interests. (Copyright © 2024 Adeolu Ogunleye et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu